Abstract
A phase 1, first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist, in healthy adult volunteers (HVS)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
